According to the latest global statistics on cancer, approximately 14.1 million new cancer cases and 8.2 million cancer-related deaths occurred worldwide in 2012[@b1]. Cancer is currently the leading cause of death worldwide, and it represents a major global health concern. Although the pathogenic factors of cancer remain unknown, complex interactions between an individual's genetic background and environmental factors have been suggested to be highly associated with cancer development[@b2].

Inherited factors leading to the development of cancer are not clearly understood, but the roles of cytokines in tumour immunity and carcinogenesis have been well established[@b3]. Th17 cells, which were identified as a new subset of T helper cells[@b4], play pivotal roles in both adaptive and innate immunity, by secreting the pro-inflammatory cytokine interleukin (IL)-17[@b5]. IL-17 has six family members (IL17A-F) that bind to five receptors (IL-17RA-RD and SEF)[@b6]. Among all IL-17 family members, IL-17A is one of the most important cytokines, and it may play a role in autoimmune diseases, chronic inflammatory diseases, and malignancies[@b7][@b8][@b9]; IL-17A has been shown to induce the production of inflammatory chemokines and cytokines by macrophages and neutrophils. More recent studies have reported that IL-17F can also induce the expression of various chemokines, cytokines, and adhesion molecules involved in inflammation-related cancer[@b10]. The rs763780 variant in the IL-17F gene can lead to a His-to-Arg substitution at amino acid position 161, and thus, inhibit the function of wild-type IL-17F. This may contribute to increased risk of several malignant tumors including gastric cancer, colorectal cancer, and breast cancer[@b11][@b12][@b13][@b14].

Meta-analysis is a statistical technique that combines results from different individual studies to produce a comprehensive assessment of the major findings with enhanced accuracy[@b15]. IL-17 polymorphism has been hypothesized to play a role in carcinogenesis, and numerous studies investigating the same have been published in the past few years[@b11][@b12][@b13][@b14][@b16][@b17][@b18][@b19][@b20][@b21][@b22][@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31]. However, these published studies have reported mixed findings. Therefore, to clarify the role of IL-17A rs2275913 and IL-17F rs763780 polymorphisms in cancer risk, we conducted a comprehensive meta-analysis of all eligible case-control studies.

Results
=======

Study characteristics
---------------------

Through primary literature retrieval from Pubmed and CNKI databases, we identified 95 studies that investigated the effect of IL-17 polymorphisms on cancer risk. After screening the titles and abstracts according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA, [Fig. 1](#f1){ref-type="fig"}), 55 studies were excluded from our meta-analysis. Then remaining 40 articles were assessed for eligibility by reading the full-text; 14 articles were excluded owing to either lack of complete data or presence of irrelevant data that focused on other IL-17 polymorphisms. Finally, 26 studies with 7,872 cases and 9,646 cancer-free controls met the inclusion criteria for our meta-analysis for assessing the influence of rs2275913 and rs763780 polymorphisms on cancer risk. Among these, 20 studies were based on the Asian population, and 6 were based on Caucasian populations. The selected studies presented data on several different cancer types: gastric, colorectal, prostate, thyroid, cervical, breast, ovary, bladder, hepatocellular, lung, and oesophageal cancer, and acute myeloid leukaemia. The main characteristics of the included studies are presented in [Table 1](#t1){ref-type="table"}. The distributions of IL-17A rs2275913 and rs763780 polymorphisms among patients and controls are shown in [Table 2](#t2){ref-type="table"}.

Quantitative synthesis results
------------------------------

IL-17A G197A polymorphism (rs2275913).

Overall, our meta-analysis found a borderline association between rs2275913 polymorphism and increased cancer risk in all genetic models (AA vs. GG: OR = 1.48, 95% CI = 1.25--1.74; AA vs. GG + GA: OR = 1.40, 95% CI = 1.19--1.65; AA + AG vs. GG: OR = 1. 22, 95% CI = 1.09--1.36, [Fig. 2](#f2){ref-type="fig"}; GA vs. GG: OR = 1.13, 95% CI = 1.01--1.28; A vs. G: OR = 1.22, 95% CI = 1.13--1.32) for all cancer types. When only studies following the Hardy--Weinberg equilibrium (HWE) were included in the analysis, a significant association was also observed under all genetic models, and these results are shown in [Table 3](#t3){ref-type="table"}.

When subgroup analysis was performed based on ethnicity, no significant correlation was observed between rs2275913 polymorphism and cancer risk in Caucasians. However, statistically significant associations were found in the following genetic models in Asians: (AA vs. GG: OR = 1.53, 95% CI = 1.29--1.81 [Fig. 3](#f3){ref-type="fig"}; AA vs. GG + GA: OR = 1.45, 95% CI = 1.24--1.70; AA + AG vs. GG: OR = 1. 20, 95% CI = 1.06--1.35; A vs. G: OR = 1.22, 95% CI = 1.12--1.32). When results were stratified by cancer type, we found a significant association between rs2275913 polymorphism and increased gastric cancer risk in three genetic models (AA vs. GG: OR = 1.62, 95% CI = 1.26--2.07; AA + AG vs. GG: OR = 1.56, 95% CI = 1.23--1.99; A vs. G: OR = 1.24, 95% CI = 1.10--1.40, [Fig. 4](#f4){ref-type="fig"}). Moreover, significant associations were observed between rs2275913 polymorphism and cervical cancer in all 5 comparison models. All comparisons are listed in [Table 3](#t3){ref-type="table"}.

IL-17F T7488C polymorphism (rs763780).

A significant association was found between rs763780 and cancer susceptibility in 3 different comparison models (CC vs. TT: OR = 1.69, 95% CI = 1.40--2.04; CC vs. TT + TC: OR = 1.64, 95% CI = 1.36--1.97; C vs. T: OR = 1.28, 95% CI = 1.11--1.47, [Fig. 5](#f5){ref-type="fig"}). The same results were observed when studies with HW disequilibrium in controls were excluded.

As shown in [Table 3](#t3){ref-type="table"}, when subgroup analyses was performed based on ethnicity, significant correlation was observed between rs763780 polymorphism and increased risk of cancer in both Caucasians and Asians. When results were stratified by cancer type, rs763780 polymorphism was found to be significantly associated with an increased risk for gastric cancer in all genetic models (CC vs. TT: OR = 1.67, 95% CI = 1.35--2.06; CC vs. TT + TC: OR = 1.59, 95% CI = 1.29--1.95; CC + TC vs. TT: OR = 1.37, 95% CI = 1.22--1.53; TC vs. TT: OR = 1.28, 95% CI = 1.13--1.45; C vs. T: OR = 1.37, 95% CI = 1.25--1.51).

Publication bias
----------------

Publication bias of the selected articles was assessed using Begg's funnel plot and Egger's test. As shown in [Fig. 6](#f6){ref-type="fig"}, the funnel plot was symmetrical in shape, and the P-value of Egger's test indicated a lack of publication bias for rs2275913 and rs763780 polymorphisms.

Heterogeneity and sensitivity analyses
--------------------------------------

Significant heterogeneities in the data of IL-17A rs2275913 and IL-17F rs763780 polymorphisms were observed in the overall meta-analysis as well as subgroup analysis ([Table 4](#t4){ref-type="table"}). Due to significant heterogeneity across studies, individual studies used in the meta-analysis were sequentially omitted to to identify the source by sensitivity analysis. The results showed that no individual study skewed the pooled OR values for rs2275913 and rs763780 polymorphisms ([Fig. 7](#f7){ref-type="fig"}).

Re-sampling statistics
----------------------

To obtain robust and replicable results, we performed the correlation analysis 10000 times using non-parametric bootstrap re-sampling method. As showed in [Supplementary Table S1 & S2](#S1){ref-type="supplementary-material"}, the results indicated that rs2275913 and rs763780 polymorphism in IL-17 gene were consistently associated with cancer risk in different genetic models (P \< 0.05).

Discussion
==========

Recently, inflammatory factors have been shown to increase the risk of developing malignant tumors. IL-17 is a key pro-inflammatory cytokine originally produced by CD4+ memory T cells, and it is involved in both innate and acquired immune responses[@b32][@b33]. Studies indicate that IL-17 is activated by microbial products, and may promote tumor growth and progression via angiogenic functions[@b34][@b35]. Aberrant levels of IL-17 have been observed in gastric, colorectal, hepatocellular, ovarian, and breast cancers[@b36][@b37][@b38][@b39][@b40].

The IL-17A rs22759133 polymorphism is located in close proximity to 2 nuclear factors activated T cell binding motifs, and it promotes production of high levels of IL-17, which in turn upregulates IL-17-mediated immune responses[@b41]. IL-17F, another important member of the IL-17 family, plays a key role in neutrophil recruitment and activation by inducing the secretion of cytokines and chemokines. IL-17F rs763780 polymorphism may inhibit the biological activity of IL-17F, and thus contribute to variations in host's susceptibility to tumors. Data indicate that IL-17A and IL-17F gene polymorphism may play important roles in the pathogenesis of cancer[@b11][@b13][@b16][@b18][@b24].

Our study indicated that the two variants of human IL-17 gene significantly increased the risk of cancer in the overall population. When we eliminated studies that deviated from the HWE, similar results were observed. Furthermore, subgroup analyses indicated that associations between these two polymorphisms and cancer risk were also ethnicity- and site-specific. According to the results, rs2275913 polymorphism was significantly associated with elevated cancer risk in Asians (mainly Chinese), but not Caucasians. When subgroup analysis was performed based on cancer types, a significant association was found between rs2275913 polymorphism and risk of gastric/cervical cancer. Interestingly, individuals with the rs2275913 AA genotype showed decreased risk of colorectal cancer as compared to individuals with the GG or GA genotypes. However, only two eligible studies examined IL-17 polymorphisms in colorectal cancer, and therefore, the results may need to be further confirmed. Interestingly, a significant association was found between the rs763780 variant and cancer risk in both the Asian and Caucasian populations. This meta-analysis is, to our knowledge, the first study showing that rs763780 polymorphism increases cancer risk in the Caucasian population.

A meta-analysis by Niu *et al.*[@b42] suggested that IL-17 polymorphisms increase the risk of cancer, particularly gastric cancer, in Asian (especially Chinese) populations; our findings were partially in line with results from this meta-analysis. Another meta-analysis by Zhao *et al.*[@b43] concluded that not rs763780, but rs2275913, polymorphism may contribute to cancer susceptibility in Asian populations. Long *et al.*[@b44] found a positive association between the two polymorphisms and the occurrence of gastric cancer in a meta-analysis, which included 7 independent, case-control studies. Other meta-analyses focused on the association between IL-17F rs763780 polymorphism and cancer risk, and the results indicated that the CC allele might increase the risk of cancer, particularly gastric cancer, in Asian populations[@b45][@b46]. All of these previous meta-analyses included fewer than 10 eligible case-control studies, with few studies examining Caucasian populations. The present meta-analysis includes 25 independent case-control studies with 7,872 cancer cases and 9,646 cancer-free controls. In addition, 6 of the included studies were based on Caucasians, to more comprehensively evaluate the relationship between IL-17 polymorphisms and cancer risk in Caucasian populations[@b14][@b16][@b24][@b27][@b31][@b47].

We conducted sensitivity analysis to confirm the validity of the results presented in our meta-analysis, and studies in which the genotype frequencies in the control group deviated from the HWE were excluded. Results showed that no individual study skewed the overall OR value.

Some limitations of the present meta-analysis should be addressed. First, although significant associations were found between the two polymorphisms and the risk of cancer in multiple genetic models, some potential sources of heterogeneity, such as source of controls, lifestyle, and environmental exposures, were not explored. In addition, some cancer types included in this meta-analysis were investigated only in 1 or 2 studies ([Supplementary Table S3](#S1){ref-type="supplementary-material"}), which led to heterogeneity in quantitative analysis. Second, the study results included in this meta-analysis were based on unadjusted analyses, and therefore, we could not estimate the risk of cancer with respect to environmental factors, age, family history, lifestyle, and other risk factors that might have influenced the pooled results. Third, we did not include any studies on the African population, and therefore, the results should be interpreted with caution when extrapolating them to the overall population. Lastly, the study with relative smaller sample size is more likely to be lack of sufficient statistical power to influence the overall results.

Our study represents a comprehensive meta-analysis of the role of IL-17A rs2275913 and IL-17F rs763780 polymorphisms in cancer risk. The results demonstrated that these two polymorphisms significantly increase the risk of development of cancer, particularly gastric cancer. Further large-scale, multicentre studies are required to confirm the pre-diagnostic effect of IL-17 gene polymorphisms on the risk of cancer.

Material and Methods
====================

Identification of eligible studies
----------------------------------

Systematic article search and quantitative analysis were performed, and written reports were generated according to the Meta-analysis of Observational Studies in Epidemiology guidelines[@b48]. Eligible studies with publication dates up to March 2015 were obtained through the Pubmed and Chinese National Knowledge Infrastructure (CNKI) databases. No language or geographical restriction was placed for study selection. The keywords search was performed with or without the Medical Subject Headings (MeSH) terms for: 'interleukin-17/IL-17', 'polymorphism', and 'cancer'. Additionally, the references in the retrieved articles were manually screened for potential eligible studies.

Inclusion and exclusion criteria
--------------------------------

Studies included in our meta-analysis were required to meet the following criteria: (1) a case-control design; (2) the study goal was to evaluate the association of IL17A rs2275913 and IL-17F rs763780 polymorphisms with cancer risk; (3) the study offered available information on genotype frequency, (4) the controls used had no malignant disease. The following were used as our exclusion criteria: (1) the study was a repeat studies, reviews, or abstracts; (2) the study design was based on family cancers; (3) the study did not include a control group; (4) the study did not investigate the effect of polymorphism; (5) duplicate data.

Data extraction
---------------

Two authors independently selected the potentially relevant studies for data extraction. We screened the titles and abstracts of the studies that met our inclusion criteria. If the content of the abstract was relevant, full articles were read to extract related information. For each eligible study included in our meta-analysis, we obtained information pertaining to first author, years of publication, country of origin, racial ancestry, cancer types, source of control, genotyping method, total number of cases and controls, and P value of Hardy--Weinberg equilibrium (HWE). All cancers were confirmed by histology or pathology. All the case and control groups were well controlled.

Resampling
----------

We applied re-sampling statistic to examine the robustness of the associations, and 10000 re-sampling analyses were conducted using the bootstrap re-sampling procedure[@b49]. All the re-sampling analyses were performed by R 3.2.2 software using non-parametric bootstrapping method. The 95% confidence intervals (95% CIs) were estimated by bias-corrected and accelerated (BCa) and overall odds ratios (ORs) were calculated containing all samples under the five different genetic models.

Statistical analysis
--------------------

The strength of association between IL-17A rs2275913 and IL-17F rs763780 polymorphisms and cancer risk was assessed as ORs with corresponding 95% CIs based on the allele frequencies in cases and controls of each study selected. The summary OR was calculated according to Woolf's method. Five different ORs were calculated: dominant model (BB+AB vs. AA), recessive model (BB vs. AA+AB), homozygote comparison (BB vs. AA), heterozygote comparison (AB vs. AA) and allele comparison (B vs. A), the A represents the major allele, and the B represents the minor allele. The Chi-square-based Q statistic was implemented to assess heterogeneity among the studies[@b50]. The controls that departures of the HWE were evaluated for each study using chi-square test.

The effect of heterogeneity using I^2^ test statistical and significance was considered at P \< 0.10. In case of a significant heterogeneity, the pooled ORs were analyzed using a random-effects model, otherwise a fixed-effects model should be used. To evaluate the ethnicity-specific and control-specific effects, subgroup analyses were conducted by source of controls, cancer types, controls whether satisfied HWE or not, and features of the population such as ethnicity. Additionally, to estimate the possible sources of bias, we considered the Egger's test and Begg's funnel plot. All statistical analyses were calculated with the software STATA (Version 11.0; Stata Corp, College Station, TX). *P*-values less than 0.05 were considered statistically significant.
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###### Characteristics of the studies included in the meta-analysis.

  First author    Year   Ethnicity   Tumor type   case   control   Genotyping medthod   Source of control    No. of SNP    cancer risk
  -------------- ------ ----------- ------------ ------ --------- -------------------- ------------------- -------------- -------------
  Hou             2015     Asian         GC       326      326         MassARRAY           Population           1, 2        No.1 yes
  Nemati          2015   Caucasian      CRC       202      203          PCR-RFLP            Hospital          1^\*^, 2         yes
  Gao             2015     Asian         GC       572      572         PCR--RFLP            Hospital          1, 2^\*^      No.2 yes
  Lv              2015     Asian         CC       264      264         PCR--RFLP           Population         1, 2^\*^      No.1 yes
  Lee             2015     Asian        PTC        94      260           TaqMan            Population            1           no risk
  Xi              2015     Asian        HCC       155      171         PCR--RFLP            Hospital            1, 2         no risk
  Wang            2014     Asian         GC       462      462         PCR--RFLP           Population           1, 2        No.1 yes
  Wróbel          2014   Caucasian      AML        62      125         PCR--RFLP           Population           1, 2        No.2 yes
  Omrane          2014   Caucasian      CRC       102      139           TaqMan            Population            1             yes
  Omrane          2014   Caucasian      CRC       102      139           TaqMan            Population            2             yes
  Yin             2014     Asian         EC       380      380          SNPscan             Hospital             1             yes
  Li              2014     Asian        HCC       395      174         PCR--RFLP            Hospital             1             yes
  Kaabachi        2014   Caucasian       LC       239      258         PCR--RFLP           Population           1, 2        No.2 yes
  Zhu             2014     Asian         GC       311      611         MassARRAY            Hospital          1, 2^\*^      No.1 yes
  Zhang           2014     Asian         GC       260      512         MassARRAY            Hospital        1^\*^, 2^\*^       yes
  Bi              2014     Asian         GC        99      150          PCR-RFLP            Hospital            1, 2         no risk
  Rafiei          2013   Caucasian       GC       161      171         PCR--RFLP            Hospital             1             yes
  Zhou            2013     Asian        BLC       301      446           TaqMan             Hospital            1, 2           yes
  Arisawa         2012     Asian         GC       337      587          PCR-SSCP            Hospital             1             yes
  Quan            2012     Asian         CC       311      463           TaqMan             Hospital            1, 2        No.1 yes
  Wang            2012     Asian         BC       491      502          SNaPshot           Population           1, 2        No.1 yes
  Ruan            2012     Asian         OC        92      38           PCR-RFLP            Hospital        1^\*^, 2^\*^     no risk
  Chen            2010     Asian         GC       1042    1090           TaqMan            Population            1           no risk
  Wu              2010     Asian         GC       1010     800         PCR--RFLP           Population           1, 2        No.2 yes
  Luo             2010     Asian         GC        24      50           PCR-RFLP            Hospital          1^\*^, 2      No.1 yes
  Shibata         2009     Asian         GC       287      524         PCR--SSCP            Hospital          1^\*^, 2      No.1 yes

^\*^The *P*-values of the Hardy-Weinberg equilibrium test of control group less than 0.05.

CRC: colorectal cancer; GC: gastric cancer; CC: cervical cancer; PTC: papillary thyroid cancer; HCC: hepatocellular carcinoma; LC: lung cancer; AML: acute myeloid leukemia; EC: esophageal cancer; BLC: bladder cancer; BC: breast cancer; OC: ovarian cancer; NA: not available; PCR-RFLP: polymerase chain reaction restriction fragment length polymorphism; SSCP: single strand conformation polymorphism; SNP: single-nucleotide polymorphisms; No. of SNP: No.1: rs2275913, No.2: rs763780.

###### IL-17 polymorphisms Genotype Distribution and Allele Frequency in Cases and Controls.

  First author      Genotype (N,%)   Allele frequency (N, %)   MAF                                                              
  ---------------- ---------------- ------------------------- ----- ----- ------- ----- ----- ----- ------- ----- ------- ----- ------
  rs2275913                                                                                                                     
   Hou 2015              326                   121             149   56     326    161   136   29     391    261    458    194   0.40
   Nemati 2015           202                   100             82    20     199    110   50    39     282    122    270    128   0.30
   Gao 2015              572                   239             250   83     573    260   241   72     728    416    761    385   0.36
   Lv 2015               264                   110             117   37     264    139   105   20     337    191    383    145   0.36
   Lee 2015               94                   28              42    24     260    76    137   47     98     90     289    231   0.48
   Xi 2015               155                   38              71    46     171    35    90    46     147    163    160    182   0.53
   Wang 2014             462                   160             211   91     462    214   190   58     531    393    618    306   0.43
   Wróbel 2014            62                   23              25    14     125    38    67    20     71     53     143    107   0.43
   Omrane 2014           102                   48              51     3     139    95    38     6     147    57     228    50    0.28
   Yin 2014              364                   104             180   80     370    117   174   79     388    340    408    332   0.47
   Li 2014               391                   110             197   84     174    50    85    39     417    365    185    163   0.47
   Kaabachi 2014         239                   147             80    12     258    166   79    13     374    104    411    105   0.22
   Zhu 2014              293                   126             122   45     550    273   216   61     374    212    762    338   0.36
   Zhang 2014            260                   110             102   48     512    258   187   67     322    198    703    321   0.38
   Bi 2014                99                   32              39    28     150    41    69    40     103    95     151    149   0.48
   Rafiei 2013           161                   56              61    44     171    78    72    21     173    149    228    114   0.46
   Zhou 2013             301                   79              154   68     446    164   204   78     312    290    532    360   0.48
   Arisawa 2012          333                   112             137   84     583    218   293   72     361    305    729    437   0.46
   Quan 2012             311                   93              142   76     463    168   215   80     328    294    551    375   0.47
   Wang 2012             491                   165             234   92     501    198   245   58     564    418    641    361   0.43
   Ruan 2012              92                   20              60    12     38     12    24     2     100    84     48     28    0.46
   Chen 2010            1,042                  300             522   220   1,090   325   541   224   1,122   962   1,191   989   0.46
   Wu 2010               945                   210             485   250    768    193   371   204    905    985    757    779   0.52
   Luo 2010               24                   11              12     1     530    58    426   46     34     14     542    518   0.29
   Shibata 2009          287                   94              124   69     523    175   299   49     312    262    649    397   0.46
  rs763780                                                                                                                      
   Hou 2015              326                   266             38    22     326    278   33    15     570    82     589    63    0.13
   Nemati 2015           200                   177             23     0     201    190   11     0     377    23     391    11    0.06
   Gao 2015              572                   420             67    85     572    472   58    42     907    237   1002    142   0.21
   Lv 2015               264                   209             35    20     264    223   30    11     453    75     476    52    0.14
   Xi 2015               155                   100             46     9     171    105   63     3     246    64     273    69    0.21
   Wang 2014             462                   349             98    15     462    362   90    10     796    128    814    110   0.14
   Wróbel 2014            62                   42              15     5     125    114   11     0     99     25     239    11    0.20
   Omrane 2014           100                   72              27     1     137    98    38     1     171    29     234    40    0.15
   Kaabachi 2014         239                   204             34     1     258    236   22     0     442    36     494    22    0.08
   Zhu 2014              293                   241             35    17     550    463   58    29     517    69     984    116   0.12
   Zhang 2014            260                   209             30    21     512    429   53    30     448    72     911    113   0.14
   Bi 2014               100                   69              22     9     150    108   35     7     160    40     251    49    0.20
   Zhou 2013             301                   240             57     4     446    317   124    5     537    65     758    134   0.11
   Quan 2012             311                   222             85     4     463    332   126    5     529    93     790    136   0.15
   Wang 2012             491                   382             103    6     502    396   99     7     867    115    891    113   0.12
   Ruan 2012              92                   13              69    10     38      2    34     2     95     89     38     38    0.48
   Wu 2010               927                   540             332   55     777    527   214   36    1412    442   1268    286   0.24
   Luo 2010               24                   14              10     0     230    176   51     3     38     10     403    57    0.21
   Shibata 2009          280                   221             55     4     523    419   100    4     497    63     938    108   0.11

A represents the major allele, B represents the minor allele. MAF: minor allele frequencies.

###### Summary of ORs and 95% CI of *IL-17A* rs2275913 and *IL-17F* rs763780 polymorphisms with cancer risk.

  Comparisons          B vs A          BB vs AA       BB vs AB + AA     BB + AB vs AA       AB vs AA                                                                           
  ------------- -------------------- ------------- ------------------- --------------- ------------------- ------------- ------------------- ------------- ------------------- -------------
  rs2275913                                                                                                                                                                    
   Overall       1.22 (1.13--1.32)    **\<0.001**   1.48 (1.25--1.74)    **\<0.001**    1.40 (1.19--1.65)   **\<0.001**   1.22 (1.09--1.36)    **0.001**    1.13 (1.01--1.28)    **0.04**
  HWE                                                                                                                                                                          
    Yes          1.23 (1.14--1.33)    **\<0.001**   1.49 (1.27--1.75)    **\<0.001**    1.39 (1.20--1.61)   **\<0.001**   1.26 (1.14--1.38)   **\<0.001**   1.17 (1.06--1.30)    **0.002**
  Ethnicity                                                                                                                                                                    
    Asian        1.22 (1.12--1.32)    **\<0.001**   1.53 (1.29--1.81)    **\<0.001**    1.45 (1.24--1.70)   **\<0.001**   1.20 (1.06--1.35)    **0.003**    1.10 (0.97--1.24)      0.13
    Caucasian    1.24 (0.94--1.63)       0.13       1.16 (0.59--2.27)       0.66        1.08 (0.51--2.28)      0.84       1.34 (0.97--1.84)      0.07       1.35 (0.90--2.03)      0.14
  Cancer type                                                                                                                                                                  
    GC           1.24 (1.10--1.40)    **\<0.001**   1.62 (1.26--2.07)    **\<0.001**    1.56 (1.23--1.99)   **\<0.001**   1.17 (0.99--1.38)      0.07       1.05 (0.89--1.25)      0.56
    CRC          1.25 (0.65--2.38)       0.51       0.61 (0.35--1.07)       0.09        0.48 (0.28--0.82)    **0.007**    1.71 (0.90--3.24)      0.10       2.10 (1.49--2.96)     \<0.001
    CC           1.38 (1.18--1.62)    **\<0.001**   1.89 (1.35--2.64)    **\<0.001**    1.66 (1.23--2.24)    **0.001**    1.43 (1.14--1.80)    **0.002**    1.29 (1.01--1.64)    **0.04**
    HCC          0.99 (0.818--1.20)      0.89       0.96 (0.65--1.41)       0.82        1.03 (0.75--1.42)      0.85       0.94 (0.68--1.28)      0.68       0.92 (0.66--1.29)      0.63
  rs763780                                                                                                                                                                     
   Overall       1.28 (1.11--1.47)     **0.001**    1.69 (1.40--2.04)    **\<0.001**    1.64 (1.36--1.97)   **\<0.001**   1.25 (1.07--1.47)    **0.001**    1.17 (1.00--1.37)      0.06
  HWE                                                                                                                                                                          
    Yes          1.25 (1.02--1.52)     **0.03**     1.70 (1.21--2.39)     **0.002**     1.69 (1.20--2.38)    **0.002**    1.21 (0.98--1.50)      0.08       1.15 (0.93--1.41)      0.20
  Ethnicity                                                                                                                                                                    
    Asian        1.06 (0.95--1.19)     **0.28**     1.54 (1.08--2.20)     **0.02**      1.55 (1.09--2.20)    **0.02**     1.04 (0.87--1.24)      0.66       0.99 (0.83--1.19)      0.95
   Caucasian     2.08 (0.94--1.63)     **0.03**     6.17 (1.50--30.0)     **0.01**      6.19 (1.36--28.1)    **0.02**     2.02 (1.08--3.76)    **0.03**     1.83 (1.08--3.11)    **0.02**
  Cancer type                                                                                                                                                                  
    GC           1.37 (1.25--1.51)    **\<0.001**   1.67 (1.35--2.06)    **\<0.001**    1.59 (1.29--1.95)   **\<0.001**   1.37 (1.22--1.53)   **\<0.001**   1.28 (1.13--1.45)   **\<0.001**
    CRC          1.40 (0.65--3.00)       0.38              --                --                --               --        1.43 (0.63--3.22)      0.39       1.42 (0.63--3.24)      0.40

A: the major allele; B: the minor allele; CI: confidence interval; OR: odds ratio; GC: Gastric cancer; CRC: colorectal cancer; CC: cervical cancer; HCC: hepatocellular carcinoma.

###### Heterogeneity-analysis results.

  Comparisons    B vs A   BB vs AA   BB vs AA+AB   BB+AB vs AA   AB vs AA                                                                
  ------------- -------- ---------- ------------- ------------- ---------- ---- ----- --------- ---- ----- --------- --- ----- --------- ---
  rs2275913                                                                                                                              
   Overall        61%     \<0.001         R            64%       \<0.001    R    70%   \<0.001   R    60%   \<0.001   R   62%   \<0.001   R
  HWE                                                                                                                                    
    Yes           58%      0.001          R            57%        0.001     R    60%   \<0.001   R    43%    0.02     R   39%    0.04     R
  Ethnicity                                                                                                                              
    Asian         62%     \<0.001         R            63%       \<0.001    R    68%   \<0.001   R    62%   \<0.001   R   60%   \<0.001   R
    Caucasian     68%       0.01          R            72%        0.007     R    80%    0.001    R    58%    0.05     R   70%    0.009    R
  Cancer type                                                                                                                            
    GC            74%     \<0.001         R            75%       \<0.001    R    79%   \<0.001   R    73%   \<0.001   R   71%   \<0.001   R
    CRC           84%       0.01          R            0%          0.48     F    0%     0.61     F    74%    0.05     R   14%    0.28     F
    CC             0%       0.45          F            0%          0.40     F    0%     0.47     F    0%     0.51     F   0%     0.51     F
    HCC            0%       0.93          F            0%          0.88     F    0%     0.56     F    0%     0.43     F   8%     0.30     F
  rs763780                                                                                                                               
   Overall        68%     \<0.001         R            0%          0.79     F    0%     0.79     F    64%   \<0.001   R   57%    0.001    R
  HWE                                                                                                                                    
    Yes           68%     \<0.001         R            0%          0.79     F    0%     0.82     F    66%   \<0.001   R   61%    0.002    R
  Ethnicity                                                                                                                              
    Asian         37%       0.12          F            0%          0.94     F    0%     0.93     F    43%    0.08     R   44%    0.08     R
    Caucasian     78%      0.003          R            17%         0.30     F    5%     0.35     F    72%    0.02     R   59%    0.06     R
  Cancer type                                                                                                                            
    GC            31%       0.17          F            6%          0.79     F    0%     0.72     F    10%    0.36     F   0%     0.48     F
    CRC           66%       0.09          R            --           --      --   --      --      --   67%    0.08     R   67%    0.08     R

A: the major allele; B: the minor allele; EM: Effects model; F: fixed effects model; R: random effects model; GC: Gastric cancer; CRC: colorectal cancer; CC: cervical cancer; HCC: hepatocellular carcinoma.

[^1]: These authors contributed equally to this work.
